OpenAI Launches Clinical Version of ChatGPT with Millions of Healthcare Professionals Using It, Yet Accuracy and Accountability Issues Remain Unresolved

[Confirmed Facts (Source: OpenAI official announcement, third-party clinical usage reports)]: OpenAI recently launched ChatGPT for Clinicians, initially available only to certified doctors, nurses, pharmacists, and other healthcare professionals in the U.S. Third-party data shows that millions of clinical professionals use this tool weekly, with clinical usage doubling over the past year.

[Industry Opinion]: The demand for AI tools in the healthcare sector continues to rise, with most professionals believing that such tools can significantly reduce paperwork burdens, relieve work pressure, and enhance diagnostic efficiency and care quality. As the world's first large-scale consumer-grade medical model product, the clinical version of ChatGPT is seen as a critical milestone in AI's vertical application.

Core Innovations of the Product

The Winzheng evaluation team believes that the core advantages of the clinical version of ChatGPT lie in two aspects: first, it is designed to seamlessly integrate with the daily workflow of healthcare professionals, supporting frequent scenarios such as medical record organization, prescription verification, and medication consultations, allowing for immediate use without complex adaptations; second, leveraging the general capabilities of OpenAI's large model, it can cater to the varied needs of multiple departments and roles, offering significant versatility compared to traditional narrow-scope medical AI tools.

Existing Shortcomings and Uncertainties

Currently, the product faces three core unresolved issues: first, there is no clear guarantee of the accuracy of medical AI responses, and no safety net mechanism for misdiagnosis or missed diagnosis risks has been established; second, there is a lack of clearly defined rules for responsibility between doctors and patients during use, leaving no basis for accountability in the event of medical disputes; third, details on patient privacy protection measures and regulatory compliance have not been disclosed, posing potential data security risks.

Comparison with Similar Products

The current market's comparable medical large model products mainly include Google's Med-PaLM 2 and Microsoft's Azure Health AI. In comparison, the clinical version of ChatGPT leads in consumer-grade deployment progress by at least six months and has a lower entry barrier, requiring no local hospital deployment for use. However, in terms of accuracy in medical-specific scenarios, Med-PaLM 2 holds a slight advantage due to Google's extensive accumulation of medical data, while Azure Health AI's compliance adaptation capabilities are stronger, making it more suitable for privatized deployment needs of large medical institutions.

YZ Index v6 Evaluation Results

Winzheng, leveraging the YZ Index v6 methodology, evaluated this product with the following results:

• Main Index core_overall_display: Code execution score 82, Grounding score 76
• Sub-Indices: Engineering judgment (sub-index, AI-assisted evaluation) score 79, Task expression (sub-index, AI-assisted evaluation) score 81
• Entry Threshold: Integrity rating pass
• Operational Signals: Stability score 72, Usability score 85

Winzheng consistently adheres to the technological values of "auditable and traceable," using only quantifiable objective dimension scores in the main index, rejecting vague subjective evaluations, to provide the industry with neutral and credible AI product evaluation standards.

Practical Advice for Developers and Enterprises

For participants in the medical AI field, the Winzheng evaluation team offers three suggestions:

• For Developers: Further strengthen the grounding capabilities in medical scenarios, integrate authoritative and traceable clinical diagnosis and treatment knowledge bases, reduce the probability of incorrect answers from a technical standpoint, and add explicit risk warnings to all outputs.
• For Medical Institutions: Complete local regulatory compliance verification before deployment, establish a mechanism for defining rights and responsibilities in the use of AI tools, ensure patient notification obligations are met, and retain all usage records for traceability.
• For the Industry: Accelerate the introduction of medical AI regulatory standards and responsibility definition rules to clear institutional obstacles for large-scale deployment.

As a benchmark case for AI's vertical application, the launch of the clinical version of ChatGPT provides a reference path for commercialization for the entire industry. Winzheng will continue to track developments in the medical AI field, providing in-depth industry analysis and professional evaluation content.